All In MedTech

Device Trial Radar · NCT06921148

Silk Bioprotein as a Wound Dressing for Double-Incision Mastectomy

The Utility of Silk Bioprotein as a Wound Dressing in Female-to-Male Double-Incision Mastectomy

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Sep 11, 2025

Primary completion

Apr 30, 2028

Study completion Jun 14, 2028

Sponsor

Lead sponsor
Indiana UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 10, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the utility of Silk bioprotein, an FDA-approved and readily available post-surgical dressing, as a wound dressing for patients undergoing double-incision mastectomy for female-to-male gender affirmation surgery.

Conditions

  • Wound Healing

Interventions

  • Sylk Wound DressingDevice

    Patients will have Silk bioprotein post-surgical dressing on one side of chest wall, and will have Dermabond/Prineo on the other side of chest wall. All patients will act as their own controls for this study. This means that all patients are both in the control group as well as the intervention group, given that these surgeries are bilateral in nature and one side of their chest will receive the interventional dressing and the other will receive the control dressing.

  • Dermabond/Prineo DressingDevice

    Patients will have Silk bioprotein post-surgical dressing on one side of chest wall, and will have Dermabond/Prineo on the other side of chest wall. All patients will act as their own controls for this study. This means that all patients are both in the control group as well as the intervention group, given that these surgeries are bilateral in nature and one side of their chest will receive the interventional dressing and the other will receive the control dressing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Medical Adhesive-Related Skin Injury (MARSI)Time frame: 12 weeks postoperatively
  2. Timeing of premature removal of postoperative dressingTime frame: 12 weeks postoperatively
  3. Postoperative wound infection and dehiscenceTime frame: Any time up until 12 weeks postoperatively

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Indiana University Health

    Indianapolis, Indiana · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.